Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience
Raymond J. So(Johns Hopkins University), Simon R. Best(Johns Hopkins University), Christopher Rayle(Johns Hopkins University), Eric H. Raabe(Johns Hopkins University), Henry H. Joo(Johns Hopkins University), Emily Y. Huang(Johns Hopkins University), Tanguy Y. Seiwert(Georgetown University)
Cited by 12
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653